http://html-tutorial-site.com/effective-web-design-determines-hotel-marketing-success.html
The FTC said late Wednesdayg the merger would substantially reduce competitionin U.S. markets for four drugs made frombloor plasma. The agency said it believes consolidation has been used by the industrtto “limit supply and drivde higher prices, rather than to provide benefits for consumers.” Last CSL — which is based in Australi a and is the parent of CSL Behring in King of Prussia, Pa. agreed to buy . of Research Triangle Park, for $3.1 billion in cash. Both companiew specialize in the development and manufacturingof blood-based biotherapeutic products.
The proposed deal calls for Peter president ofCSL Behring, to lead the combined compang and report to Brian CEO of CSL Ltd. “Wr strongly disagree with the FTC’xs decision to challenge the deal,” McNamed said. “CSL intends to vigorously opposethe FTC’sx actions. The FTC has failed to recognize that this combinatiois pro-competitive, provides significant efficienciesx that will improve the suppluy of biotherapies, and is beneficial to the patientt community. … I’m particularly surprisesd and disappointed withthe commission's theorgy that there is any coordination in the plasmqa industry.
This sector is intensely competitive with manufacturersdrapidly expanding. A combined company will have the abilitty to more quickly and efficiently meet the expectec continuing demand for plasmz therapies that are critical to patients suffering frombleedinb disorders, immune deficiencies, genetic emphysema, and othert rare diseases.” McNamee said the merger would result in an improver ability for CSL to supply therapies to patientes and customers through expanded and integratef manufacturing with “greater efficiency and fewer bottlenecks.
” He added CSL disagreez with the FTC’s view of the competitive landscape, noting four “strong manufacturers” would remain after the transaction.
Nenhum comentário:
Postar um comentário